Zevra Therapeutics, Inc. (ZVRA)
Nasdaq · Pharmaceutical Preparations · Manufacturing · CIK 1434647 · fiscal year ends in Dec
Closing price $10.36 on 29 Oct 2026; 52-week range $8.10 to $14.75.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $136.1M
- Revenue growth
- 119.4%
- Net income, last twelve months
- $58.3M
- Earnings per share
- $0.94
- Gross margin
- 95.5%
- Operating margin
- 60.5%
- Net margin
- 42.8%
- Return on equity
- 26.8%
- Market value
- $614.5M
- Price to earnings
- 11.0x
- Cash
- $145.3M
- Debt
- $0
- Debt to equity
- 0.00
- Shares outstanding
- 59.3M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $106.5M | -$62.9M | $83.2M | $1.35 | -$2.4M | 10-K filed 9 Mar 2026 |
| FY2024 | 31 Dec 2024 | $23.6M | -$87.0M | -$105.5M | -$2.28 | -$69.7M | 10-K filed 12 Mar 2025 |
| FY2023 | 31 Dec 2023 | $27.5M | -$49.6M | -$46.0M | -$1.30 | -$33.8M | 10-K filed 1 Apr 2024 |
| FY2022 | 31 Dec 2022 | $10.2M | -$42.5M | -$26.8M | -$0.78 | -$18.8M | 10-K filed 7 Mar 2023 |
| FY2021 | 31 Dec 2021 | $28.6M | $7.7M | -$8.6M | -$2.11 | $10.3M | 10-K filed 31 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $39.7M | $8.8M | $0.14 |
| Q1 FY2026 | 31 Mar 2026 | $36.2M | $37.9M | $0.60 |
| Q4 FY2025 | 31 Dec 2025 | $34.1M | $12.2M | $0.21 |
| Q3 FY2025 | 30 Sep 2025 | $26.1M | -$544.0K | -$0.01 |
| Q2 FY2025 | 30 Jun 2025 | $25.9M | $74.7M | $1.21 |
| Q1 FY2025 | 31 Mar 2025 | $20.4M | -$3.1M | -$0.06 |
| Q4 FY2024 | 31 Dec 2024 | $12.0M | -$35.7M | -$0.69 |
| Q3 FY2024 | 30 Sep 2024 | $3.7M | -$33.2M | -$0.69 |
Company events
The newest 8-K filings of 207 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 5 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 5 Jun 2026 | 8-K | Shareholder vote | 5.07, 9.01 |
| 6 May 2026 | 8-K | Results | 2.02, 9.01 |
| 16 Mar 2026 | 8-K | Material agreement, Agreement ended, Investor update | 1.01, 1.02, 7.01, 9.01 |
| 9 Mar 2026 | 8-K | Results, Leadership change | 2.02, 5.02, 9.01 |
| 17 Dec 2025 | 8-K | Leadership change | 5.02, 9.01 |
| 2 Dec 2025 | 8-K | Leadership change, Investor update | 5.02, 7.01, 9.01 |
| 20 Nov 2025 | 8-K | Leadership change, Investor update | 5.02, 7.01, 9.01 |
| 5 Nov 2025 | 8-K | Results | 2.02, 9.01 |
| 12 Aug 2025 | 8-K | Results | 2.02, 9.01 |
| 29 May 2025 | 8-K | Shareholder vote | 5.07 |
| 13 May 2025 | 8-K | Results | 2.02, 9.01 |
Every filing
The newest filings with the SEC of 436 held.
| Filed | Form | Period |
|---|---|---|
| 5 Aug 2026 | 10-Q | 30 Jun 2026 |
| 5 Aug 2026 | 8-K | 5 Aug 2026 |
| 5 Jun 2026 | 8-K | 4 Jun 2026 |
| 6 May 2026 | 10-Q | 31 Mar 2026 |
| 6 May 2026 | 8-K | 6 May 2026 |
| 20 Apr 2026 | DEF 14A | 4 Jun 2026 |
| 6 Apr 2026 | PRE 14A | 6 Apr 2026 |
| 16 Mar 2026 | 8-K | 12 Mar 2026 |
| 9 Mar 2026 | S-8 | – |
| 9 Mar 2026 | 10-K | 31 Dec 2025 |
| 9 Mar 2026 | 8-K | 4 Mar 2026 |
| 17 Dec 2025 | 8-K | 11 Dec 2025 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 12 Oct 2026 | Mcfarlane Neil F., President and CEO | Sale under a trading plan | 20,000 | $11.25 | $224.9K | 417,225 | 13 Oct 2026 |
| 14 Aug 2026 | Thompson Rahsaan, Chief Legal & Compliance | Sale under a trading plan | 42,666 | $11.13 | $474.8K | 37,569 | 17 Aug 2026 |
| 10 Aug 2026 | Watton Corey Michael, Director | Sale outside a trading plan | 12,300 | $11.25 | $138.4K | 1,800 | 12 Aug 2026 |
| 22 Jun 2026 | Thompson Rahsaan, Chief Legal & Compliance | Sale under a trading plan | 34,557 | $12.68 | $438.3K | 80,235 | 23 Jun 2026 |
| 11 May 2026 | Thompson Rahsaan, Chief Legal & Compliance | Sale under a trading plan | 1,794 | $11.30 | $20.3K | 48,125 | 13 May 2026 |
| 9 Feb 2026 | Mcfarlane Neil F., President and CEO | Sale under a trading plan | 14,625 | $8.56 | $125.2K | 387,225 | 10 Feb 2026 |
| 3 Feb 2026 | Sangiovanni Timothy J., SVP, Finance & Corp Controller | Sale under a trading plan | 3,000 | $9.18 | $27.5K | 29,590 | 4 Feb 2026 |
| 3 Feb 2026 | Schafer Joshua, CCO | Sale under a trading plan | 10,500 | $9.19 | $96.5K | 62,278 | 4 Feb 2026 |
| 2 Feb 2026 | Mcfarlane Neil F., President and CEO | Sale under a trading plan | 91,000 | $9.38 | $853.4K | 364,350 | 2 Feb 2026 |
| 30 Jan 2026 | Sangiovanni Timothy J., SVP, Finance & Corp Controller | Sale under a trading plan | 1,750 | $8.82 | $15.4K | 20,924 | 2 Feb 2026 |
| 30 Jan 2026 | Thompson Rahsaan, Chief Legal & Compliance | Sale under a trading plan | 4,080 | $8.83 | $36.0K | 49,919 | 2 Feb 2026 |
| 30 Jan 2026 | Quartel Adrian W, Chief Medical Officer | Sale under a trading plan | 4,533 | $8.83 | $40.0K | 9,723 | 2 Feb 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 13 Oct 2026 | NEIL F MCFARLANE, Director, Officer | 20,000 | $227.8K | 12 Oct 2026 |
| 14 Aug 2026 | RAHSAAN THOMPSON, Officer, Secretary | 42,666 | $477.0K | 14 Aug 2026 |
| 8 Jul 2026 | JOHN BODE, Director | 10,516 | $156.2K | 8 Jul 2026 |
| 11 May 2026 | Rahsaan Thompson, Officer, Chief Legal & Compliance / Secretary | 36,351 | $404.6K | 11 May 2026 |
| 16 Mar 2026 | RAYMOND L CLIFTON, Officer | 345,428 | $3.4M | 16 Mar 2026 |
| 2 Feb 2026 | NEIL F MCFARLANE, Director, Officer | 105,625 | $950.6K | 2 Feb 2026 |
| 30 Jan 2026 | RAHSAAN THOMPSON, Officer, Secretary | 4,080 | $36.1K | 30 Jan 2026 |
| 30 Jan 2026 | ADRIAN QUARTEL, Officer | 4,533 | $40.2K | 30 Jan 2026 |
| 30 Jan 2026 | TIMOTHY SANGIOVANNI, Officer | 4,750 | $42.1K | 30 Jan 2026 |
| 30 Jan 2026 | JOSHUA SCHAFER, Officer | 13,875 | $122.9K | 30 Jan 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 14 Aug 2026 | Woodline Partners LP | 13G amended | 8.1% | 4.8M |
| 6 Aug 2026 | FMR LLC | 13G amended | 8.3% | 4.9M |
| 31 Jul 2026 | Vanguard Capital Management | 13G | 5.11% | 3.0M |
| 6 May 2026 | FMR LLC | 13G | 5.5% | 3.2M |
| 27 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 14 Nov 2025 | Woodline Partners LP | 13G amended | 6.2% | 3.5M |
| 13 Nov 2025 | Adage Capital Management, L.P. | 13G amended | 3.96% | 2.2M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 6.2M | -12.89% | 7.08 |
| 30 Sep 2026 | 7.1M | +24.55% | 7.16 |
| 15 Sep 2026 | 5.7M | -0.56% | 6.33 |
| 31 Aug 2026 | 5.8M | -10.81% | 7.46 |
| 14 Aug 2026 | 6.5M | -9.27% | 5.76 |
| 31 Jul 2026 | 7.1M | -8.51% | 4.4 |
| 15 Jul 2026 | 7.8M | +20.12% | 5.44 |
| 30 Jun 2026 | 6.5M | -0.46% | 4.31 |
Funds that hold it
From each fund's latest Form 13F.
175 funds held it at 30 Jun 2026: 90 added and 40 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| BlackRock, Inc. | 5,108,871 | $73.3M | +652,395 |
| FMR LLC | 4,915,717 | $70.5M | +1,703,840 |
| Woodline Partners LP | 4,785,771 | $68.6M | +1,334,828 |
| Nantahala Capital Management, LLC | 3,594,952 | $51.6M | – |
| Vanguard Capital Management LLC | 2,638,910 | $37.8M | +169,582 |
| State Street Corp. | 1,681,999 | $24.1M | +120,430 |
| Geode Capital Management, LLC | 1,540,936 | $22.1M | +169,079 |
| D. E. Shaw & Co., Inc. | 1,306,949 | $18.7M | +460,492 |
| Qube Research & Technologies Ltd | 1,241,343 | $17.8M | +399,024 |
| Morgan Stanley | 1,203,875 | $17.3M | +11,613 |
Peers
Companies in the same industry.
- Eli Lilly & Co. (LLY): revenue $86.5B, market value $1.29T
- Johnson & Johnson (JNJ): revenue $99.3B, market value $662.4B
- AbbVie Inc. (ABBV): revenue $64.4B, market value $513.9B
- Merck & Co., Inc. (MRK): revenue $66.6B, market value $361.0B
- Novartis AG (NVS): revenue $54.5B, market value $307.3B
- AstraZeneca PLC (AZN): revenue $58.7B, market value $270.6B
- Abbott Laboratories (ABT): revenue $46.6B, market value $180.9B
- Novo Nordisk A/S (NVO): revenue $46.8B, market value $174.8B
- Pfizer Inc. (PFE): revenue $63.7B, market value $170.7B
- Vertex Pharmaceuticals Inc. (VRTX): revenue $12.6B, market value $136.8B